Projects per year
Fingerprint
Dive into the research topics where Kah-Whye Peng is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Mayo Clinic Ovarian Cancer SPORE
Kaufmann, S. S. H. (PI), Maia, A. A. G. (CoPI), Oberg, A. L. (CoPI), Bell, D. (CoPI), Bible, K. C. (CoPI), Moriarity, B. (CoPI), Cliby, W. A. (CoPI), Couch, F. J. (CoPI), Goode, E. L. (CoPI), Fields, A. P. (CoPI), Galanis, E. (CoPI), Haluska, P. R. J. (CoPI), Hartmann, L. C. (CoPI), Karnitz, L. M. (CoPI), Kaufmann, S. H. (CoPI), Keeney, G. (CoPI), Knutson, K. L. (CoPI), Lengyel, E. (CoPI), Lingle, W. L. (CoPI), Long, H. (CoPI), Sherman, M. E. (CoPI), Block, M. S. (CoPI), Peng, K.-W. (CoPI), Shridhar, V. (CoPI), Weroha, S. (CoPI) & Huang, Y. Y. (CoPI)
9/1/09 → 8/31/27
Project: Research project
-
Phase I trial of intravenous vesicular stomatitis virus for treatment of metastatic endometrial cancer
Bakkum-Gamez, J. N. (PI), Block, M. S. (CoPI) & Peng, K.-W. (CoPI)
5/4/17 → 4/30/18
Project: Research project
-
Phase 2: NIS proteins with altered anion specificity
Suksanpaisan, L. (PI), Peng, K.-W. (CoPI) & Russell, S. J. (CoPI)
5/1/17 → 3/31/20
Project: Research project
-
-
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer
Galanis, E. (PI) & Peng, K.-W. (CoPI)
7/1/09 → 8/31/14
Project: Research project
-
Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus
Jiang, H., Peng, K. W. & Russell, S. J., Feb 4 2026, In: Molecular Therapy. 34, 2, p. 734-747 14 p.Research output: Contribution to journal › Review article › peer-review
Open Access -
Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition
Zhang, L., Pham, L., Steele, M. B., Jenks, N., Nace, R., Russell, S. J. & Peng, K. W., Jun 18 2026, In: Molecular Therapy Oncology. 34, 2, 201226.Research output: Contribution to journal › Article › peer-review
Open Access -
Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12
Jiang, H., Nace, R., Ferguson, C., Zhang, L., Peng, K. W. & Russell, S. J., Jan 21 2025, In: Cell Reports Medicine. 6, 1, 101874.Research output: Contribution to journal › Article › peer-review
Open Access -
Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12
Jiang, H., Nace, R., Carrasco, T. F., Zhang, L., Peng, K. W. & Russell, S. J., Mar 25 2024, In: Journal for ImmunoTherapy of Cancer. 12, 3, e008307.Research output: Contribution to journal › Article › peer-review
Open Access -
Oncolytic α-herpesvirus and myeloid-tropic cytomegalovirus cooperatively enhance systemic antitumor responses
Jiang, H., Nace, R., Ariail, E., Ma, Y., McGlinch, E., Ferguson, C., Fernandez Carrasco, T., Packiriswamy, N., Zhang, L., Peng, K. W. & Russell, S. J., Jan 3 2024, In: Molecular Therapy. 32, 1, p. 241-256 16 p.Research output: Contribution to journal › Article › peer-review
Open Access